Burden of carbapenem-resistant organisms in the Frankfurt/Main Metropolitan Area in Germany 2012/2013 – first results and experiences after the introduction of legally mandated reporting

BMC Infectious Diseases

Ursel Heudorf²  René Gottschalk²  Volkhard AJ Kempf¹  Angelika Hausemann²  Niels Kleinkauf² 

[1] University Hospital, Johann Wolfgang Goethe-University, Frankfurt/Main, Germany;Public Health Authority of Frankfurt/Main, Breite Gasse 28, D- 60313 Frankfurt, Germany

关键词: Population-based surveillance;    Epidemiology;    Mandatory reporting;    Carbapenemase;    Multidrug resistance;    Gram-negative bacteria;   

Others  :  1127182
DOI  :  10.1186/1471-2334-14-446

 received in 2014-03-14, accepted in 2014-08-12,  发布年份 2014

【 摘 要 】

Background

The federal state of Hesse, Germany, introduced a laboratory-based reporting scheme for carbapenem-resistant organisms (CROs).

Method

The results of the first year of mandated reporting of CROs from April 2012 through March 2013 to the Public Health Authority of Frankfurt/Main, responsible for a population of 700,000 inhabitants, are described.

Results

Within a period of 12 months 243 CROs were notified to the health authority. Of these 213 isolates had been reported from 16 of the 17 hospitals in Frankfurt/Main, 6 from ambulatory settings and 24 from clinics outside of Frankfurt/Main. Mean incidence rate per 1,000 patient days in hospitals was 0.138 (range 0.02-0.28).

Conclusion

In Frankfurt/Main almost all hospitals have reported CROs in the study period though the frequency of isolation varies strongly and many facilities only report CROs sporadically. Molecular data indicate a high diversity of different carbapenemases. Autochthonous transmission must be assumed despite the absence of major outbreaks. Rapid and coordinated efforts by clinicians and health departments are crucial to control the spread of CRO infections. The mandatory reporting scheme provides important data to guide the implementation of preventive measures.

【 授权许可】

   
2014 Kleinkauf et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Rodloff AC, Goldstein EJ, Torres A: Two decades of imipenem therapy. J Antimicrob Chemother 2006, 58(5):916-929.
• [2]Gupta N, Limbago BM, Patel JB, Kallen AJ: Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention. Clin Infect Dis 2011, 53(1):60-67.
• [3]Cantón R, Akóva M, Carmeli Y, Giske CG, Glupczynski Y, Gniadkowski M, Livermore DM, Miriagou V, Naas T, Rossolini GM, Samuelsen Ø, Seifert H, Woodford N, Nordmann P, European Network on Carbapenemases: Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. Clin Microbiol Infect 2012, 18(5):413-431.
• [4]Hawkey PM: The growing burden of antimicrobial resistance. J Antimicrob Chemother 2008, 62(Suppl. 1):i1-i9.
• [5]Nordmann P, Naas T, Poirel L: Global spread of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 2011, 17(10):1791-1798.
• [6]Gröbner S, Linke D, Schütz W, Fladerer C, Madlung J, Autenrieth IB, Witte W, Pfeifer Y: Emergence of carbapenem-non-susceptible extended-spectrum beta-lactamase-producing Klebsiella pneumoniae isolates at the university hospital of Tuebingen, Germany. J Med Microbiol 2009, 58:912-922.
• [7]Wendt C, Schütt S, Dalpke AH, Konrad M, Mieth M, Trierweiler-Hauke B, Weigand MA, Zimmermann S, Biehler K, Jonas D: First outbreak of Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae in Germany. Eur J Clin Microbiol Infect Dis 2010, 29(5):563-570.
• [8]Robert Koch-Institute: Current situation of carbanemenresistant gramnegative bacteriae in Germany. Epidemiol Bull 2013, 19:167-171. (German). http://www.rki.de/DE/Content/Infekt/EpidBull/epid_bull_node.html webcite
• [9]European Centre for Disease Prevention and Control: Updated risk assessment on the spread of NDM and its variants within Europe. Stockholm: ECDC; 2011. http://ecdc.europa.eu/en/publications/Publications/1111_TER_Risk-assessment-NDM.pdf webcite
• [10]Pfeifer Y, Witte W, Holfelder M, Busch J, Nordmann P, Poirel L: NDM-1-producing Escherichia coli in Germany. Antimicrob Agents Chemother 2011, 55(3):1318-1319.
• [11]Glasner C, Albiger B, Buist G, Tambić Andrasević A, Canton R, Carmeli Y, Friedrich AW, Giske CG, Glupczynski Y, Gniadkowski M, Livermore DM, Nordmann P, Poirel L, Rossolini GM, Seifert H, Vatopoulos A, Walsh T, Woodford N, Donker T, Monnet DL, Grundmann H, European Survey on Carbapenemase-Producing Enterobacteriaceae (EuSCAPE) Working Group: Carbapenemase-producing Enterobacteriaceae in Europe: a survey among national experts from 39 countries, February 2013. Euro Surveill 2013., 18(29)
• [12]The Hessian Minister of Social Affairs: Enactment on the extension of the mandatory notification according to the Protection against Infection Act (IfSGMeldeVO) of 29th November 2011. 2011.
• [13]Hauri AM, Kaase M, Hunfeld KP, Heinmüller P, Imirzalioglu C, Wichelhaus TA, Fitzenberger J, Wirtz A: Results on the mandatory notification of carbapenem-resistant Gram-negative bacteria, Hesse, Germany, January 2012 – April 2013. GMS Infect Dis 2014, 2:Doc04.
• [14]European Centre for Disease Prevention and Control: Antimicrobial resistance surveillance in Europe 2012. Annual Report of the European Antimicrobial Resistance Surveillance Network (EARS-Net). Stockholm: ECDC; 2013. http://www.ecdc.europa.eu/en/publications/surveillance_reports/Pages/index.aspx webcite
• [15]Robert Koch-Institute: Surveillance on antibiotic resistance. https://ars.rki.de/ webcite
• [16]Grundmann H, Livermore DM, Giske CG, Canton R, Rossolini GM, Campos J, Vatopoulos A, Gniadkowski M, Toth A, Pfeifer Y, Jarlier V, Carmeli Y, CNSE Working Group: Carbapenem-non-susceptible Enterobacteriaceae in Europe: conclusions from a meeting of national experts. Euro Surveill 2010, 18:15(46).
• [17]Hunfeld KP, Bingold T, Brandt C, Witte W, Brade V, Wissing H: Multiresistant Acinetobacter baumannii in an intensive care unit. Epidemiology, hygiene management, and therapeutic options. 2007. [Ulmer Symposium Krankenhausinfektionen, 17–20 April 2007; Ulm, Germany; abstr. V106. (German)]
• [18]Pfeifer Y, Wilharm G, Zander E, Wichelhaus TA, Göttig S, Hunfeld KP, Seifert H, Witte W, Higgins PG: Molecular characterization of blaNDM-1 in an Acinetobacter baumannii strain isolated in Germany in 2007. J Antimicrob Chemother 2011, 66(9):1998-2001.
• [19]Göttig S, Pfeifer Y, Wichelhaus TA, Zacharowski K, Bingold T, Averhoff B, Brandt C, Kempf VA: Global spread of New Delhi metallo-beta-lactamase 1. Lancet Infect Dis 2010, 10:828-829.
• [20]Commission for Hospital Hygiene and Infectious Disease Prevention (KRINKO) at the Robert Koch Institute (RKI): Prevention strategies for infections or colonisations with multiresistant gram-negative bacilli. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2012, 55(10):1311-1354. (German)
• [21]Centers for Disease Control and Prevention (CDC): Guidance for Control of Carbapenem-resistant Enterobacteriaceae (CRE). Available from: http://www.cdc.gov/hai/organisms/cre/cre-toolkit/ webcite
• [22]The Hessian Minister of Social Affairs. Hessian Hygiene Act (HHygVO): Gesetz- und Verordnungsblatt für das Land Hessen, Teil I – 8. 2011, 745-750.